RxDoctor Payments Data

Lawrence Hess

Family · Granbury, TXNPI 1720176217

Payments from drug & device makers

$3,272in general payments, 2019–2025

Across 243 payments — averaging $13.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$688
  • AstraZeneca$497
  • Novo Nordisk$432
  • Pfizer$401
  • Lilly USA, LLC$234
  • Merck$170
  • plus $851 from 22 others

What the payments were for

  • Food & beverage$3,272100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,272 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$40,225
Medicare patients
117
Services billed
1,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf)Adalimumab12$163,481
OzempicSemaglutide81$92,376
FarxigaDapagliflozin Propanediol95$87,314
JardianceEmpagliflozin70$81,191
MounjaroTirzepatide62$64,394
EliquisApixaban62$61,644
RexultiBrexpiprazole31$50,690
UbrelvyUbrogepant27$38,797
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$37,548
VraylarCariprazine Hcl23$31,437
MyrbetriqMirabegron31$28,858
Combivent RespimatIpratropium/Albuterol Sulfate43$24,637
JanuviaSitagliptin Phosphate13$21,976
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$18,499
XareltoRivaroxaban27$16,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Ubrelvy, Vraylar, Linzess$688$243,42080 claims
Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat, Spiriva Respimat$46$131,070146 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$497$129,898168 claims
Novo NordiskOzempic$432$92,37681 claims
Lilly USA, LLCMounjaro$234$64,39462 claims
PfizerEliquis$401$61,64462 claims
Otsuka America Pharmaceutical, Inc.Rexulti$139$50,69031 claims
GSKTrelegy Ellipta, Breo Ellipta$92$26,50134 claims
MerckJanuvia$170$21,97613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Granbury

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →